Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group.

Pierre-Etienne Heudel,Jean-Sébastien Frenel,Cécile Dalban,Fernando Bazan,Florence Joly,Antoine Arnaud,Cyril Abdeddaim,Annick Chevalier,Paule Augereau,Patricia Pautier,Camille Chakiba,Benoit You,Laurence Lancry Lecomte,Gwenaelle Garin,Virginie Marcel,Jean-Jacques Diaz,Isabelle Treilleux,David Pérol,Michel Fabbro,Isabelle Ray-Coquard

Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group.

2021

5507Background: Endometrial carcinoma is generally hormone dependent and aromatase inhibitors are used in routine practice before or after 1st line chemotherapy (CT) for HR positive patients. Dereg...

Keywords:

Internal medicine
Metastatic endometrial cancer
Carcinoma
Medicine
Oncology
in patient
Chemotherapy
Aromatase
Hormone receptor
Hormone
Anastrozole

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations